Oklahoma Heart Institute (OHI) was the first facility in the country to use the next-generation Supira percutaneous left ventricular assist device (pVAD) as part of the SUPPORT II research trial.
What is the Supira pVAD?
The Supira pVAD helps the left ventricle pump blood through the heart during high-risk stenting (HRPCI) used while treating blockages in the heart. It is an investigational device with a smaller profile than currently available VADs that offers more support for the patient’s heart.
What is the SUPPORT II research trial?
This is a prospective, randomized controlled study designed to assess the safety and efficacy of Supira’s next-generation pVAD in patients undergoing high-risk percutaneous coronary intervention (HRPCI). HRPCI is used to treat blocked arteries when open-heart surgery is not a treatment option. The study will enroll up to 385 patients at up to 40 U.S. sites.
It will compare the Supira pVAD device’s efficiency to that of existing pVAD technology.
Why does it matter?
The profile and efficiency of this new device could potentially expand the available treatment population and improve effectiveness and safety of similar procedures. OHI is the only facility in the region participating in this trial.